AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22016074 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock following ATP
Number of subjects: 1530
Study 22016074 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ATP
Number of subjects: 1530
Study 22016074 — intervention group
Group type: COMPARATOR
Intervention: Shock therapy
Number of subjects: 1530
Study 22016074 — intervention group
Group type: COMPARATOR
Intervention: Episodes between 200 and 250 bpm
Number of subjects: 1530
Study 22016074 — intervention group
Group type: COMPARATOR
Intervention: Episodes >250 bpm
Number of subjects: 1530
Study 21177179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy plus sulfasalazine delivered via a colon therapy system
Number of subjects: 54
Study 21177179 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine delivered via retention enema (Control)
Number of subjects: 54
Study 21177179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine delivered via colon therapy system
Number of subjects: 54
Study 18025627 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual SICS superior incision
Number of subjects: 64
Study 18025627 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual SICS temporal incision
Number of subjects: 64
Study 18025627 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification clear corneal incision
Number of subjects: 64
Study 18025627 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification scleral pocket incision
Number of subjects: 64
Study 16108781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led inpatient unit
Number of subjects: 175
Study 16108781 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 175
Study 11822750 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 337
Study 11822750 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg
Number of subjects: 337
Study 9725371 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve blockade (T3 through T6) with bupivacaine through an indwelling catheter
Number of subjects: 30
Study 9725371 — intervention group
Group type: COMPARATOR
Intervention: Combination of local anesthetics (bupivacaine) and opioid analgesics (fentanyl) through a thoracic epidural catheter
Number of subjects: 30
Study 8151479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat formula
Number of subjects: 10
Study 8151479 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate formula
Number of subjects: 10
Study 3166629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption
Number of subjects: 18
Study 3166629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption with a meal
Number of subjects: 18
Study 3166629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption after a high-energy meal
Number of subjects: 18
Study 3166629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption with different meal compositions
Number of subjects: 18
Study 28895175 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (nurses and physiotherapists) providing general case management, general information, specific information, and continuity and safety over 12 months with one or more home visits per month.
Number of subjects: 153
Study 28895175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 153
Study 27072372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation (FATmax) intensity, 5 days/week, 1 hour/day for 10 weeks
Number of subjects: 30
Study 27072372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 24508649 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous co-activation for 3 hours
Number of subjects: 0
Study 24508649 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous co-activation for 3 hours
Number of subjects: 0
Study 22895063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (<125/<80 mm Hg)
Number of subjects: 3518
Study 22895063 — intervention group
Group type: COMPARATOR
Intervention: Usual control (125-134/80-84 mm Hg)
Number of subjects: 3518
Study 22895063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients
Number of subjects: 3518
Study 20441414 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with amniotic membrane implantation and mitomycin C (MMC)
Number of subjects: 30
Study 20441414 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC) only
Number of subjects: 30
Study 17921398 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal serum zinc concentrations
Number of subjects: 578
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy by fluvoxamine
Number of subjects: 32
Study 16509426 — intervention group
Group type: COMPARATOR
Intervention: Controlled therapy
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop test
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS‐R
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: Y‐BOCS mean score
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCI score
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRS
Number of subjects: 32
Study 16509426 — intervention group
Group type: EXPERIMENTAL
Intervention: STAI scores
Number of subjects: 32
Study 12505235 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory BP monitoring in a subgroup of the HOPE study
Number of subjects: 0
Study 12505235 — intervention group
Group type: COMPARATOR
Intervention: Office BP measurements
Number of subjects: 0
Study 10767520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus L-thyroxine (75 mcg/day for 3 months)
Number of subjects: 16
Study 10767520 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg/day for 5 days/month for 3 months)
Number of subjects: 16
Study 10767520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus L-thyroxine
Number of subjects: 16
Study 10767520 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 16
Study 8866594 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 microg formoterol b.i.d.
Number of subjects: 221
Study 8866594 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 microg formoterol b.i.d.
Number of subjects: 221
Study 8866594 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 microg formoterol b.i.d.
Number of subjects: 221
Study 8866594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 1386856 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 217
Study 1386856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 1386856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociotropy-Autonomy distinction
Number of subjects: 217
Study 1386856 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogeneity and autonomy
Number of subjects: 217
Study 6437815 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS‐NTG (25 mg per 10 cm2)
Number of subjects: 10
Study 31656173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (ET) 3 times per week for 12 weeks
Number of subjects: 60
Study 31656173 — intervention group
Group type: COMPARATOR
Intervention: No attention control group (CG)
Number of subjects: 60
Study 28704213 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual pad HPV testing
Number of subjects: 529
Study 25952589 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK II intervention (n=123)
Number of subjects: 254
Study 25952589 — intervention group
Group type: COMPARATOR
Intervention: Information, Support, and Referral (n=131)
Number of subjects: 254
Study 25952589 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK II intervention
Number of subjects: 254
Study 25952589 — intervention group
Group type: COMPARATOR
Intervention: Information, Support, and Referral
Number of subjects: 254
Study 25322847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph
Number of subjects: 73
Study 25322847 — intervention group
Group type: COMPARATOR
Intervention: Sphygmocor
Number of subjects: 73
Study 22560323 — intervention group
Group type: EXPERIMENTAL
Intervention: Coapsys device implantation
Number of subjects: 1
Study 19067606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd dose of 1.25 microg H5N1 vaccine
Number of subjects: 0
Study 19067606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd dose of 2.5 microg H5N1 vaccine
Number of subjects: 0
Study 19067606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd dose of 5 microg H5N1 vaccine
Number of subjects: 0
Study 19067606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd dose of 10 microg H5N1 vaccine
Number of subjects: 0
Study 17544875 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose inactive trivalent influenza vaccine
Number of subjects: 80
Study 17544875 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and immunomodulatory therapy
Number of subjects: 80
Study 17544875 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 80
Study 15718325 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six weekly sessions of 2 hours)
Number of subjects: 262
Study 15718325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 262
Study 11545630 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (22.0-24.9)
Number of subjects: 21121
Study 11545630 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean BMI (< 22.0)
Number of subjects: 21121
Study 11545630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight BMI (25.0-29.9)
Number of subjects: 21121
Study 11545630 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese BMI (>= 30.0)
Number of subjects: 21121
Study 11545630 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and neovascular ARM
Number of subjects: 21121
Study 9286000 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived alcohol availability
Number of subjects: 3372
Study 9286000 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking in a public location
Number of subjects: 3372
Study 8335174 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 17
Study 8335174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 3524182 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.0 million units) followed by 72 hours of heparin infusion
Number of subjects: 38
Study 3524182 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by heparin infusion
Number of subjects: 38
Study 2493413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/h NTG infusion
Number of subjects: 10
Study 2493413 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 2493413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/h NTG infusion after 12-hour infusion-free interval
Number of subjects: 10
Study 31855057 — intervention group
Group type: EXPERIMENTAL
Intervention: JOIN for ME
Number of subjects: 66
Study 31855057 — intervention group
Group type: COMPARATOR
Intervention: JOIN for ME enhanced program
Number of subjects: 66
Study 30858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Microteaching combined with the BOPPPS method
Number of subjects: 105
Study 30858273 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 105
Study 28619229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 0
Study 28619229 — intervention group
Group type: COMPARATOR
Intervention: Sputum smear microscopy (standard of care)
Number of subjects: 0
Study 25037243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD) - 500 μg/0.1 ml
Number of subjects: 57
Study 25037243 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) - 1.25 mg
Number of subjects: 57
Study 25037243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD)
Number of subjects: 57
Study 25037243 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 57
Study 25037243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 23980355 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine therapy + Xuebijing (XBJ)
Number of subjects: 32
Study 23980355 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 32
Study 21459690 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (4 sessions per week at 50% to 80% of repetition maximum for 8 weeks)
Number of subjects: 16
Study 21459690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 16
Study 17987348 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' responses to patients' requests for antidepressants
Number of subjects: 22
Study 17987348 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' cognitive reactions to patient requests
Number of subjects: 22
Study 17987348 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' prescribing behavior influenced by patient requests
Number of subjects: 22
Study 17987348 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of time and attitudes on prescribing
Number of subjects: 22
Study 18942528 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15798812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-retroviral therapy plus N-acetyl-L-cysteine (NAC) supplementation (600 mg/day)
Number of subjects: 30
Study 15798812 — intervention group
Group type: COMPARATOR
Intervention: Anti-retroviral therapy plus placebo
Number of subjects: 30
Study 11789125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (donepezil, rivastigmine, metrifonate)
Number of subjects: 0
Study 11789125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo extract EGb 761R
Number of subjects: 0
Study 11789125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9815743 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) at 150 IU/kg
Number of subjects: 43
Study 9815743 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) at 300 IU/kg
Number of subjects: 43
Study 9815743 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 43
Study 7687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (Selddane)
Number of subjects: 10
Study 7687510 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 3720387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic intercostal nerve block using phenol
Number of subjects: 73
Study 3720387 — intervention group
Group type: COMPARATOR
Intervention: Control (no nerve block)
Number of subjects: 73
Study 30789575 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary strength training program (twice per week for 8 weeks)
Number of subjects: 20
Study 30789575 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performing 8 weeks of fencing training (4 times per week) without supplementary strength training
Number of subjects: 20
Study 31227373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionation (42·7 Gy in seven fractions, 3 days per week for 2·5 weeks)
Number of subjects: 1200
Study 31227373 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (78·0 Gy in 39 fractions, 5 days per week for 8 weeks)
Number of subjects: 1200
Study 31227373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionation
Number of subjects: 1200
Study 31227373 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 1200
Study 29145540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily)
Number of subjects: 60
Study 29145540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 60
Study 29145540 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-session after-school SRH programme
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: School health services
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with sexual debut before baseline
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who had been victims of sexual violence or intimate partner violence (IPV)
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants motivated by a wish to receive new knowledge, life coaching and positive attitudes towards the intervention
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: Unavailability of safe transport and domestic responsibilities
Number of subjects: 1576
Study 26141155 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attitudes about the intervention
Number of subjects: 1576
Study 23322502 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii group
Number of subjects: 36
Study 23322502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 22027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (IM) group: 750 ml of IMPACT plus half‐size hospital meals orally from 5 days before to the day before surgery
Number of subjects: 26
Study 22027191 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group: Conventional hospital meals
Number of subjects: 26
Study 18298219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing varnish
Number of subjects: 40
Study 18298219 — intervention group
Group type: EXPERIMENTAL
Intervention: Brackets
Number of subjects: 40
Study 18298219 — intervention group
Group type: COMPARATOR
Intervention: Bands
Number of subjects: 40
Study 18298219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 40
Study 17211119 — intervention group
Group type: EXPERIMENTAL
Intervention: PMS nutritional education program for 8 weeks
Number of subjects: 56
Study 14627214 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Tampax tampon
Number of subjects: 110
Study 14627214 — intervention group
Group type: COMPARATOR
Intervention: Control Tampax tampon
Number of subjects: 110
Study 11210392 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (OTC)
Number of subjects: 0
Study 11210392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9248049 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication about highly overlapping information
Number of subjects: 432
Study 9248049 — intervention group
Group type: COMPARATOR
Intervention: No communication with nonoverlapping information
Number of subjects: 432
Study 9248049 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication, overlap, and target consistency
Number of subjects: 432
Study 9248049 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication and stimulus overlap
Number of subjects: 432
Study 9248049 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiver communication
Number of subjects: 432
Study 8391282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Number of subjects: 60
Study 8391282 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin 1 million IU
Number of subjects: 60
Study 8391282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3103163 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniracetam 1 g daily for 3 months
Number of subjects: 44
Study 3103163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31778599 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19∗2 allele (homozygote or mutation heterozygote)
Number of subjects: 199
Study 31778599 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 (C3435C>T) polymorphism
Number of subjects: 199
Study 31778599 — intervention group
Group type: EXPERIMENTAL
Intervention: Total incidence of allelic disorders of low drug absorption and metabolism
Number of subjects: 199
Study 28779961 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling during heel lance
Number of subjects: 74
Study 28779961 — intervention group
Group type: COMPARATOR
Intervention: Routine heel lance (control)
Number of subjects: 74
Study 26867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine 8.121 mg
Number of subjects: 84
Study 26867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine 9.012 mg
Number of subjects: 84
Study 23170788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical exams plus fetal fibronectin (FFN)
Number of subjects: 76
Study 23170788 — intervention group
Group type: COMPARATOR
Intervention: Cervical exams only (Control)
Number of subjects: 76
Study 21044870 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum treatment
Number of subjects: 0
Study 21044870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18727138 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy (RARC)
Number of subjects: 30
Study 18727138 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 30
Study 18727138 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 30
Study 16569804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 16569804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16569804 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0